IDWeek 2014: Complera Matches Atripla for Women Starting HIV Treatment


The Complera (rilpivirine/tenofovir/emtricitabine) single-tablet regimen worked as well as Atripla (efavirenz/tenofovir/emtricitabine) for treatment-naive women and was somewhat better tolerated in the open-label STaR trial, according to a report at the IDWeek 2014 meeting last week in Philadelphia.

Cathy Creticos from the Howard Brown Health Center in Chicago reported findings from STaR, the first head-to-head comparison of Complera vs Atripla in people starting antiretroviral therapy (ART) for the first time. Unlike the earlier ECHO and THRIVE trials, which compared the same drug combinations taken as separate pills plus placebos -- requiring multiple daily pills -- all participants in STaR took a single tablet once-daily.

The full study included 786 participants, of whom more than 90% were men. The present analysis focused on the 56 women in the study, half assigned to take Complera and half to Atripla. Among the women, about 30% were white and 65% were black (compared with 70% and 21%, respectively, among the men). The mean baseline CD4 T-cell count was approximately 330 cells/mm3 (compared with 395 cells/mm3 for the men); 14% in the Complera arm and 36% in the Atripla arm had baseline viral load >100,00 copies/mL.


"Overall, [Complera] was non-inferior to [Atripla] in terms of virologic suppression at both Week 48 and Week 96 with low rates of virologic failure in both arms," the researchers concluded. "There was no difference in rates of virological suppression between genders."



C Creticos, C Brinson, C McDonald, et al. STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naive Females at Week 96. IDWeek 2014. Philadelphia, October 8-12, 2014. Abstract 537.